Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting immunostaining in relation to complex human pathologies.
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding. Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Registration enables users to use special features of this website, such as past
order histories, retained contact details for faster checkout, review submissions, and special promotions.
NR1H3 / LXR Alpha
nuclear receptor subfamily 1, group H, member 3
Liver X receptor alpha (LXR alpha), a NR1 Thyroid Hormone-Like Receptor, has been shown to affect the transport and catabolism of cholesterol as well as fatty acid metabolism. LXR alpha also appears to be an important insulin mediating factor in the regulation of lipogenesis. LXR alpha is known to be activated by oxysterols and to regulate a wide range of genes, including members of the ATP-binding cassette (ABC) superfamily of transporter proteins (ABCA1 and ABCG1), surface constituents of plasma lipoproteins like apolipoprotein E, and cholesterol ester transport protein. The induced expression of LXR alpha may be related to foam-cell formation in atherosclerotic lesions. As a result, LXR alpha has been suggested as a potential therapeutic target for treating atherosclerosis. LXR alpha forms a heterodimer with RXR alpha and binds the DR4-type cis-element. Recently LXR alpha has been shown to act as a cAMP-responsive nuclear modulator of renin and c-myc expression, suggesting a possible involvement of LXR alpha in the cardiovascular system and in general gene transcription.
Intrauterine growth restriction combined with a maternal high-fat diet increases hepatic cholesterol and low-density lipoprotein receptor activity in rats. Zinkhan EK, Zalla JM, Carpenter JR, Yu B, Yu X, Chan G, Joss-Moore L, Lane RH. Physiological reports. 2016 4: (WB; Human)[Full Text Article]
Related Antibodies: LS-C172075.
Prenatal Exposure to a Maternal High Fat Diet Increases Hepatic Cholesterol Accumulation in Intrauterine Growth Restricted Rats in Part Through MicroRNA-122 Inhibition of Cyp7a1. Zinkhan EK, Yu B, Schlegel A. Frontiers in physiology. 2018 May;9:645. (Human)[Full Text Article]
Related Antibodies: LS-C172075.
Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal. Schmitt J, Kong B, Stieger B, Tschopp O, Schultze SM, Rau M, Weber A, M[Character fc]llhaupt B, Guo GL, Geier A. Liver international : official journal of the International Association for the Study of the Liver. Apr;35:1133-44. [Full Text Article]
Related Antibodies: LS-B3526.